MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Short-term investments$264,277K Cash and cashequivalents$62,103K Prepaid expenses andother current assets$22,320K Total current assets$348,700K Right of use assets -operating leases$370K Other assets$156K Deferred offering costs$69K Total assets$349,295K Total liabilities andstockholders' equity$349,295K Total stockholders'equity$323,980K Total liabilities$25,315K Accumulated deficit-$447,961K Accumulated othercomprehensive income (loss)-$270K Additional paid-in capital$772,206K Total currentliabilities$24,995K Operating leaseliabilities, net of current...$320K Common stock 0.0001 parvalue, 200,000,000...$5K Accrued expenses$16,169K Accounts payable$8,727K Operating leaseliabilities$99K
Balance Sheet

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)

source: myfinsight.com